Citi Says Synergy Pharmaceuticals Inc Most Likely Potential Target In Their Coverage Universe For Takeda, Following A FT Article On Takeda's Appetite For U.S. Acquisitions

September 14, 2016 9:35 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

A Dilutive Offering In The Offing? Oppenheimer Downgrades Synergy Pharma

Thoughts On Synergy Pharma's Valuation As Cantor Initiates At Overweight

What Synergy's New Patents Mean For Its Commercial Prospects

Analyst: Synergy Pharma Could Achieve Sustainable Profitability By 2018